Effects of Protocatechuic Acid on Endothelial Function and HDL Functionality in Hypercholesterolemic Subjects: A Randomized Double-Blind Placebo-Controlled Trial.

What was studied

This was a randomised, double-blind trial with a placebo. People were put in groups by chance. It enrolled 150 adults aged 35 to 65 years with high cholesterol. Each day they took 20 mg of protocatechuic acid (PCA) or a placebo capsule. This went on for 12 weeks. The team measured vessel function and HDL traits. They did this at the start, at 6 weeks, and at 12 weeks.

What they found

PCA improved dilation of the brachial artery compared with placebo. It also raised blood cGMP. HDL3 rose and HDL2 fell. Total HDL and pre-β-HDL did not change significantly. PCA also raised the eNOS activity of HDL. In the PCA group, changes in this activity tracked changes in dilation, cGMP, and HDL3.

What it means for patients

The authors conclude that PCA improves vessel function and HDL function. This was in people with high cholesterol. They say the HDL subclass mix shifted as well.

Why it is not certain yet

The authors call these findings hypothesis-generating. They say larger, long-term trials are needed to confirm them. This trial lasted 12 weeks and had 150 people.

Source

Effects of Protocatechuic Acid on Endothelial Function and HDL Functionality in Hypercholesterolemic Subjects: A Randomized Double-Blind Placebo-Controlled Trial.

We restate facts from the source record in our own words. The original wording belongs to its publisher.